AU
UK
CA
NZ
IND
US
Last update at 2026-06-09T17:54:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Wed 30 Apr 25, 08:01 PMMIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Wed 26 Feb 25, 09:01 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -29.99100M | -10.03800M | -25.58500M | -3.39700M | -3.39700M |
| Minority interest | - | - | - | - | - |
| Net income | -30.19700M | -10.28500M | -25.58000M | -29.97900M | -29.97900M |
| Selling general administrative | 208.79M | 198.36M | 181.02M | 252.63M | 252.63M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 219.53M | 215.33M | 256.17M | 322.73M | 322.73M |
| Reconciled depreciation | 4.05M | 5.18M | 6.86M | 7.58M | 6.92M |
| Ebit | -24.97100M | -5.00500M | -20.71400M | -3.92400M | -3.92400M |
| Ebitda | -20.92900M | 0.18M | -12.68300M | 2.99M | 2.99M |
| Depreciation and amortization | 4.04M | 5.18M | 8.03M | 6.92M | 6.92M |
| Non operating income net other | - | -0.02300M | -8.20400M | 0.28M | 0.53M |
| Operating income | -24.97100M | -5.00500M | -20.71400M | -3.92400M | -3.92400M |
| Other operating expenses | 292.81M | 263.60M | 319.97M | 363.04M | 363.04M |
| Interest expense | 5.02M | 4.98M | -4.70800M | 0.00000M | 0.00000M |
| Tax provision | 0.21M | 0.25M | -12.25900M | -0.00500M | 26.58M |
| Interest income | - | - | - | - | - |
| Net interest income | -5.01600M | -4.98000M | -7.94100M | -4.70800M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 0.05M | 1.03M | 0.45M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.21M | 0.25M | -0.00500M | 26.58M | 26.58M |
| Total revenue | 267.84M | 258.62M | 299.25M | 359.11M | 359.11M |
| Total operating expenses | 244.50M | 220.31M | 276.89M | 326.65M | 326.65M |
| Cost of revenue | 48.32M | 43.28M | 43.08M | 36.39M | 36.39M |
| Total other income expense net | -5.02000M | -5.03300M | -4.87100M | 0.53M | 0.53M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -30.19700M | -10.28500M | -49.28400M | -25.58000M | -29.97900M |
| Net income applicable to common shares | -36.77700M | -10.28500M | -83.32800M | -25.58000M | -29.97900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 239.05M | 171.43M | 187.93M | 167.17M | 122.84M |
| Intangible assets | 5.26M | 5.85M | 5.38M | 7.78M | 9.61M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.75M | 2.63M | 2.81M | 6.06M | 5.82M |
| Total liab | 96.33M | 189.42M | 187.85M | 132.77M | 73.19M |
| Total stockholder equity | 142.72M | -17.98800M | 0.08M | 34.40M | 49.66M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 36.96M | 34.71M | 34.97M | 1.40M | 56.68M |
| Common stock | 0.15M | 0.11M | 0.11M | 0.11M | 0.11M |
| Capital stock | 0.15M | 0.11M | 92.61M | 91.68M | 0.11M |
| Retained earnings | -133.67800M | -17.98800M | -161.70900M | -102.14000M | -76.56000M |
| Other liab | - | 2.33M | 4.87M | 3.75M | 0.62M |
| Good will | 19.44M | 19.98M | 19.98M | 19.98M | 19.98M |
| Other assets | - | 0.15M | 0.19M | 0.38M | 0.44M |
| Cash | 82.00M | 65.95M | 87.08M | 69.07M | 45.12M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 46.01M | 43.56M | 42.36M | 67.32M | 71.55M |
| Current deferred revenue | -1.54800M | - | - | 53.46M | - |
| Net debt | -33.90100M | -17.35600M | -38.95600M | -3.41300M | -45.11800M |
| Short term debt | 1.55M | - | - | 3.75M | 3.75M |
| Short long term debt | - | - | - | - | 3.75M |
| Short long term debt total | 48.10M | 48.59M | 48.13M | 65.66M | 65.66M |
| Other stockholder equity | 276.25M | -92.60800M | 161.68M | 136.43M | 144.69M |
| Property plant equipment | - | 11.26M | 13.86M | 11.44M | 15.72M |
| Total current assets | 164.26M | 134.20M | 148.52M | 123.25M | 74.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -43.81600M | -25.27700M | 91.42M | 6.64M |
| Short term investments | - | - | - | - | - |
| Net receivables | 53.87M | 43.79M | 41.10M | 32.34M | 0.45M |
| Long term debt | 48.10M | 48.59M | 48.13M | 47.70M | 61.91M |
| Inventory | 21.02M | 13.18M | 11.39M | 9.10M | 15.99M |
| Accounts payable | 9.05M | 8.85M | 7.38M | 8.71M | 14.86M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -239.04700M | - | -92.49400M | -91.56800M | -18.58700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.11M | 0.11M | 0.11M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -161.70900M | -151.42400M | -102.14000M |
| Treasury stock | - | - | -4.01700M | -7.44900M | -10.80600M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.20M | 0.15M | 0.19M | 0.44M | 1.79M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 74.79M | 37.23M | 39.41M | 43.92M | 48.80M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | 61.91M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2.66000M | -3.39500M | -4.55500M | 2.72M | 0.78M |
| Change to liabilities | 1.05M | -0.32600M | 0.20M | -8.94500M | 23.82M |
| Total cashflows from investing activities | -2.66000M | -3.39500M | -4.55500M | 0.50M | -9.22000M |
| Net borrowings | -0.04100M | -0.03800M | -29.04600M | 64.22M | -0.00300M |
| Total cash from financing activities | -0.58000M | -3.35200M | 62.86M | -8.93400M | -8.93400M |
| Change to operating activities | -2.77700M | -17.09500M | -1.48600M | -10.26200M | 18.34M |
| Net income | -30.19700M | -10.28500M | -25.58000M | -29.97900M | -29.97900M |
| Change in cash | -21.13300M | -8.72900M | 23.95M | 17.64M | 17.64M |
| Begin period cash flow | 87.08M | 95.81M | 45.12M | 27.48M | 27.48M |
| End period cash flow | 65.95M | 87.08M | 69.07M | 45.12M | 45.12M |
| Total cash from operating activities | -17.89300M | -1.98200M | -39.41200M | 35.80M | 35.80M |
| Issuance of capital stock | 0.00000M | 0.00000M | 100.00M | - | - |
| Depreciation | 4.05M | 5.18M | 7.58M | 6.92M | 6.92M |
| Other cashflows from investing activities | - | 0.07M | -0.32700M | -0.46600M | -0.57900M |
| Dividends paid | -0.65100M | - | -100.00000M | - | - |
| Change to inventory | -1.79400M | -1.02800M | 6.88M | -6.51900M | -6.51900M |
| Change to account receivables | -5.55000M | -4.93000M | -10.93800M | 16.45M | -0.19000M |
| Sale purchase of stock | -1.19000M | -4.75100M | -1.47400M | -12.48600M | -4.01700M |
| Other cashflows from financing activities | 0.65M | 1.44M | 66.21M | 3.56M | 36.17M |
| Change to netincome | 16.82M | 16.14M | 22.13M | 11.92M | 42.39M |
| Capital expenditures | 2.68M | 3.47M | 2.22M | 10.03M | 9.42M |
| Change receivables | - | -4.93000M | -3.09600M | -10.93800M | - |
| Cash flows other operating | - | 10.42M | -8.09900M | -21.76500M | -0.97400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -8.72900M | 26.74M | 23.95M | 17.64M |
| Change in working capital | -9.02900M | -14.07700M | -20.05300M | 18.60M | -0.43500M |
| Stock based compensation | 12.67M | 14.76M | 12.06M | 14.77M | - |
| Other non cash items | 4.62M | 2.12M | -15.00400M | -0.05300M | 14.71M |
| Free cash flow | -20.57700M | -5.45200M | -41.63000M | 25.77M | 25.77M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group Inc |
-0.005 0.14% | 3.69 | 15.02 | 20.12 | 2.94 | 6.64 | 2.84 | 22.54 |
| NVO Novo Nordisk A/S |
0.85 2.08% | 41.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.35 0.85% | 41.60 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.02 0.91% | 446.98 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
4.25 0.70% | 615.59 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
| Name | Title | Year Born |
|---|---|---|
| Mr. K. Todd Newton | Interim CEO & Director | 1963 |
| Mr. Peter Martin Carlson CPA | Chief Financial Officer | 1964 |
| Mr. William F. Hulse IV | Gen. Counsel & Chief Admin. Officer | 1974 |
| Dr. Rohit Kashyap Ph.D. | Pres of Wound Care & Surgical | 1971 |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Pres of Regenerative Medicine & Biologics Innovation | 1951 |
| Mr. Scott M. Turner | Sr. VP of Operations & Procurement | 1965 |
| Mr. William L. Phelan | Sr. VP & Chief Accounting Officer | NA |
| Mr. Matthew M. Notarianni | Head of Investor Relations | NA |
| Mr. Mark P. Graves | Sr. VP & Chief Compliance Officer | 1966 |
| Hilary Dixon | VP of Investor Relations & Corp. Strategic Communications | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...